Cepheid, a California-based molecular diagnostics company, and the Foundation for Innovative New Diagnostics (FIND) announced a new collaboration to accelerate the development of a rapid HIV viral load test. This viral load test will run on the platform of Cepheid’s GeneXpert, the ground-breaking rapid test to diagnose drug-susceptible and drug-resistant tuberculosis. Given the high rates of TB/HIV co-infection, especially in southern Africa, a diagnostic with both these capabilities could be incredibly beneficial in diagnosing and managing these two deadly infectious diseases. To read the full press announcement, click here.
In places where rates of diseases that include malaria, HIV and tuberculosis are highest, the obstacles to tackling them begin with diagnosis. While the people most […]
Raise profile, funding of global TB response to match advances seen in HIV, Malaria efforts report says
Over the first 15 years of this century, as efforts against the “big three” global infectious diseases — HIV, malaria and tuberculosis — accelerated, the numbers […]
From a human-scented mosquito trap to rapid diagnostics, USAID funds research and development against Zika
Agency picks 21 of 900 ideas from around the world A research center in Tanzania will develop inexpensive sandals treated to ward off mosquito bites. Investigators […]
Examination of West Africa Ebola crisis highlights fault lines revealed in previous outbreaks, opportunities to expand knowledge
The threat of Ebola across Guinea, Liberia, and Sierra Leone in 2014 had been recognized about three months earlier when an unrelated outbreak began in an isolated […]